MedPath
HSA Approval

Elfabrio Concentrate for Solution for Infusion 2 mg/ml

SIN17186P

Elfabrio Concentrate for Solution for Infusion 2 mg/ml

Elfabrio Concentrate for Solution for Infusion 2 mg/ml

February 20, 2025

ORIENT EUROPHARMA PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantORIENT EUROPHARMA PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INFUSION, SOLUTION CONCENTRATE

INTRAVENOUS

Medical Information

A16AB20

Manufacturer Information

ORIENT EUROPHARMA PTE LTD

Chiesi Farmaceutici S.p.A.

Active Ingredients

Pegunigalsidase alfa

2 mg/ml

Pegunigalsidase alfa

Documents

Package Inserts

Elfabrio Concentrate for Solution for Infusion PI.pdf

Approved: February 20, 2025

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Elfabrio Concentrate for Solution for Infusion 2 mg/ml - HSA Approval | MedPath